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1. Introduction 
1.1 Thyrotoxicosis and thyrotoxic cardiomyopathy – Current state  
Thyrotoxicosis is a common syndrome, and according to the Wickham Survey its prevalence 
is 2% among women and 0.2% in men in the areas with normal iodine consumption. Over 
the 20-year follow-up the incidence of thyrotoxicosis was 0.8:1000 in women and 0.6:1000 in 
men (Bird et al,1977). 
Subclinical thyrotoxicosis (ST) is defined by low or undetectable serum thyrotropin 
stimulating hormone (TSH) and normal free thyroxin (FT4) and free triiodthyronin (FT3) 
concentrations (Biondi & Cooper, 2008). Although thyroid hormones are defined as being 
within normal range in patients with ST, they are often at the upper limit of the reference 
range, and thus sufficiently increased to suppress TSH and potentially produce abnormal 
tissue effects.  
The prevalence of subclinical thyrotoxicosis varies from 0.6 to 16% % (Biondi et al., 2002; 
Wang & Crapo, 1997; Samuels, 1998)  depending on such risk factors as age (it is twice 
higher in elderly people), iodine deficiency (5-times higher in the areas of iodine deficiency), 
and decreased TSH level. All authors agree that ST is more common compared to overt 
thyrotoxicosis.  
There are exogenous (iatrogenic) and endogenous causes of thyrotoxicosis. Exogenous 
thyrotoxicosis usually is subclinical and mainly is caused by suppressive therapy with L-
thyroxin leading to the decrease of TSH below normal values. It is commonly present in 
postoperative patients with differentiated thyroid cancer (papillary and follicular) as the 
mean of cancer recurrence prevention. This group of patients gets prolonged (2 years and 
longer) high-dose L-thyroxin therapy, and is considered in studies regarding side-effects of 
suppressive treatment. At the same time patients with benign thyroid nodules get short 
courses (6-12 months) of suppressive therapy, leading to a less decrease of TSH (above 0,1 
mIU/l). According to the majority of data 1/2-2/3 of ST cases are exogenous (Figge et al., 
1994; Canaris et al., 2002; Hoogendoorn et al., 2004).       
Endogenous thyrotoxicosis can be also divided into immune (Graves’ disease, “Hashitox”) 
and non-immune (toxic (pretoxic) thyroid adenoma and toxic multinodular goiter)  (Ross, 
1996; Marqusee et al., 1998; Al-Abadi, 2001). Graves’ disease is the most common cause of 
overt thyrotoxicosis.  
Thyrotoxic cardiomyopathy (TCMP) is a threatening complication of thyrotoxicosis 
increasing risk of disability and mortality. Until recently myocardial alterations observed in 
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thyrotoxicosis were considered favorable regarding prognosis because of the high 
reversibility if euthyroid state is quickly achieved.  However, long-term follow-up studies 
demonstrated that the involution of the changes is not always complete. Some irreversible 
histological alterations of myocardium are found in patients who had thyrotoxicosis in past: 
necrosis of the hypertrophied myocytes and fibrosis development (Ortmann et al., 1999). 
Myocardial fibrosis has been also detected by radioimmunoimaging with antimyosin 
antibodies in patients with TCMP complicated by heart failure (HF) (Martí et al., 1997). 
There is a current evidence that even successfully treated thyrotoxicosis is associated with 
the worse prognosis. Thus, cardiovascular (hypertension, valvular diseases, heart failure, 
and to a lesser extent coronary artery disease) mortality is 1.2 higher in these patients, and 
cerebrovascular mortality is 1.4 higher than in general population (Osman et al., 2002). 
Persistent cardiovascular alterations are considered an evident cause of the increased 
mortality in thyrotoxicosis (Metso et al., 2007; Sheu et al., 2010). Health effects of subclinical 
thyrotoxicosis are not fully recognized, and some questions are still unsolved. However, 
quite large amount of publications of the last two decades verify deleterious effects of 
thyrotoxicosis, and uppermost, on cardiovascular system (Biondi et al., 2002). Moreover, 
there is evidence of the increased mortality in subclinical thyrotoxicosis (Sgarbi, 2010). Thus, 
in British study among patients over 60 years of age mortality (5 year follow-up) in subjects 
with TSH below normal values was about twice that of euthyroid subjects (Parle et al., 2001). 
Cardiovascular diseases were the most common cause of lethal events. Therefore, 
cardiovascular complications of thyrotoxicosis are of great medical importance.  
2. Definition – Epidemiology of thyrotoxic cardiomyopathy and its clinical 
variants  
Thyrotoxic cardiomyopathy defines a myocardial damage caused by the toxic effects of 
abundant thyroid hormones (TH) (Report of the 1995 WHO/ISFC) that result in altered 
energy production by myocytes (oxidative phosphorylation, glycolysis), intracellular 
metabolism (protein synthesis) and myofibril contractile function (Klein, 1990).  
The main manifestations of thyrotoxic cardiomyopathy (TCMP) are left ventricular 
hypertrophy (LVH) (Ching et al., 1996, Dorr et al., 2005), heart rhythm disturbances 
(usually, atrial fibrillation (AF)) (Dunn et al., 1986; Frost et al.,  2004), dilation of the heart 
chambers and heart failure (HF) (Dougherty & Craige, 1973; Siu et al., 2007), pulmonary 
hypertension (PH) (Chu et al., 2002; Rubin &  Badesch, 2006), and diastolic dysfunction. 
Epidemiology data on TCMP are currently lacking. This is due to the lack of diagnostic 
criteria and to the late introduction of the term “thyrotoxic cardiomyopathy” in clinical and 
research practice that occurred only after implementation of WHO classification of 
cardiomyopathies (Report of the 1995 WHO/ISFC). 
Meanwhile et al. (1959) found that 4 out of 9 postmortem examinations detected no other 
cause for severe congestive HF but thyrotoxicosis, and that 64 out of 150 patients (43%) with 
thyrotoxicosis had cardiovascular complications in the absence of any known pre-existing 
heart disease. 
The available evidence provides only data on the incidence of TCMP manifestations, 
including the most severe ones - AF and HF.  
The incidence of heart rhythm disturbances in thyrotoxicosis varies in a wide range. Sinus 
tachycardia is the most common occurring in 42%-73% [Burggraaf J et al 2001, Cacciatori V, 
et al. 1996]. Tachycardia at rest and during sleep is a typical symptom in thyrotoxicosis. 
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Heart rate at rest is known to be one of the most important reserve parameters and a 
predictor of fatal cardiovascular complications. Elevated resting heart rate is associated 
with higher mortality. Risk of death from all causes is three-times higher in subjects with 
resting heart rate of 90-99 versus 60 beats per minute. Predictive value of heart rate is higher 
in hypertensive people and those with coronary artery disease. High resting heart rate 
might cause worsening of hypertension, increases risk of acute cardiovascular events, 
coronary artery disease, fatal ventricular arrhythmias as the most common causes of a 
sudden death, blood pressure elevation and heart failure development. Sinus bradycardia is 
rather rare in thyrotoxicosis.  
Atrial fibrillation takes second place among heart rhythm disturbances occurring in 9%-
23% of thyrotoxic patients compared to 0.4%-1.0% in general population (Petersen & 
Hansen, 1988; Presti & Hart, 1989; Parle et al., 1991; Frost et al., 2004). This is the most 
common cardiovascular complication of thyrotoxicosis), and is associated with high 
morbidity and mortality related to the thromboembolism (Staffurt et al., 1977). The 
complication rate varies widely and will be discussed later. Thus, Sandler and Wilson (1959) 
and Petersen and Hansen (1988) found 14% and 14.9% occurrence of atrial fibrillation, 
respectively, in the population of subjects without concomitant heart disease. In a study of 
women with different cardiac pathology atrial fibrillation was diagnosed in 67% of subjects 
with thyrotoxicosis (Ladenson, 1993).  
Subclinical thyrotoxicosis is associated with the increased risk of atrial fibrillation (Auer et 
al., 2001). In the Framingham study at 20-year follow-up the incidence of AF was 25% in 
patients with low TSH that is 3 times as high as in euthyroid patients (7%) ( Sawin et al., 
1994). The prevalence of AF seems to be comparable in overt and subclinical thyrotoxicosis. 
According to Auer J. et al. (2001) it was 13.8%  in patients with overt thyrotoxicosis, 12.7 % 
in  subclinical thyrotoxicosis, and 2.3 % in euthyroid subjects (Auer et al., 2001). Extrasystole 
(5%-7%), paroxysmal tachycardia (0.2%-3.3%) and atrial flutter (approximately 1.4%) rarely 
occur in thyrotoxicosis. 24-hour ECG monitoring studies demonstrated that atrial heart 
rhythm disturbances are typical for thyrotoxicosis while ventricular ones usually occur only 
in severe cases and in subjects with concomitant cardiovascular diseases (table1). 
 
Arrhythmias Frequency (%)                                                      
Sinus tachycardia 42-73  
Atrial fibrillation 9-23 
Extrasystole 5-7 
Atrial flutter  1,2-2,3 
Paroxysmal tachycardia               0,2-3,3 
AV-block 2,7-5 
Sick sinus syndrome can develop in elderly people 
Table 1. Arrhythmias in thyrotoxicosis 
The evidence on left ventricular hypertrophy (LVH) prevalence is not enough. On the one 
hand, some authors found the increase in left ventricular myocardium mass in both overt 
(Nixon et al., 1979; Auer et al., 2001; Dorr et al., 2005; Marcisz et al., 2006) and subclinical 
(Ching et al., 1996; Biondi, 1999, 2000; Auer, 2001)  thyrotoxicosis. On the other hand, there 
are not enough studies considering LVH occurrence in thyrotoxicosis and factors 
contributing its development, geometry type (eccentric or concentric), and reversibility. 
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According to the epidemiology study (1510 patients over 45 years of age) by M. Dörr et al. 
(2005) LVH was diagnosed in 57,1% of patients with thyrotoxicosis, compared to 10.5% in 
euthyroid individuals. Therefore, thyrotoxicosis was considered an independent predictor 
of LVH (odds ratio, 13.65; 95% confidence interval, 2.83–65.75; p < 0.01).  We have analyzed 
the occurrence of LVH and factors contributing its development and reversibility among in-
patients with thyrotoxicosis. The LVH occurrence was 22.7% that is lower compared to the 
mentioned data. We included patients under 55 years of age without concomitant 
cardiovascular pathology, and this could be a possible reason for the lower prevalence 
(Babenko  et al., 2011). 
The increase of left ventricular myocardial mass index (LVMMI) was demonstrated in all 
studies regarding subclinical thyrotoxicosis (Ching et al., 1996; Auer, 2001), however, the 
values did not meet diagnostic criteria for left ventricular hypertrophy (Biondi, 1999, 
2000).  
Only women with overt thyrotoxicosis, unlike those with subclinical thyrotoxicosis, had 
high values of LVMMI (meeting LVH criteria) associated with the decrease of end-diastolic 
left ventricular volume and development of concentric LVH (CLVH), as reported by 
Donatelli M et al. (2003) on the other hand, the majority of studies demonstrate increase of 
both LVMMI and end-diastolic left ventricular volume and development of eccentric LVH 
(ELVH) (Levina, 1989; Marcisz et al., 2006; Babenko et al., 2007, 2008, 2011).   
Concentric remodeling of left ventricle occurs in ST (Biondi et al., 2002; Donatelli et al., 
2003), while eccentric remodeling is more common in overt thyrotoxicosis.   
Prevalence of heart failure also widely varies - from 12% to 68% (Forfar et al., 1982; 
Hrnciar, 2002; Roffi et al., 2003); up to 90% of patients with thyrotoxicosis and HF develop 
AF (Siu et al., 2007).  
Dilated TCMP as a threatening complication of thyrotoxicosis should be mentioned (Goland 
et al., 1999). Siu C-W. et al. (2007) reported 1% occurrence of dilated thyrotoxic 
cardiomyopathy in patients with thyrotoxicosis, and one thirds of cases is irreversible. 
Thyrotoxicosis accounts for 1% of the reasons of dilated TCMP (Lutton et al., 2001).  
Association between thyrotoxicosis and pulmonary hypertension (PH) has been described 
as early as in the beginning of 1980s (Mier et al., 1989) and the linking mechanisms are 
discussed till nowadays (Yanai-Landau et al., 1995; Barst & Loyd, 1998; Menzel et al., 2000; 
Armigliato et al., 2006).  Graves’ (autoimmune) disease accounts for the most cases of PH: 
47-65% of patients with diffuse goiter have PH (Mercé et al., 2005, Armigliato et al., 2006; 
Yung et al., 2006), such a high prevalence can be explained by both severe form of 
thyrotoxicosis and autoimmune effects (Yanai-Landau et al., 1995; Chu et al., 2002). The 
occurrence of PH in subclinical thyrotoxicosis is almost unknown. According to our data, 
the prevalence of PH was 29% in ST, and 39.6% in overt thyrotoxicosis.  
The prevalence of mitral valve prolapse is 18-41% in thyrotoxicosis compared to 6-20% in 
general population (Brauman et al., 1985, Kahaly, 1986, Evangelopoulou et al., 1999).  
3. The pathogenesis of thyrotoxic cardiomyopathy and its manifestations 
3.1 Cardiovascular effects of thyroid hormones  
Thyroid hormones (TH) affect cardiovascular system through three main intracellular 
processes in cardiomyocytes: energy production (oxidative phosphorylation, glycolysis), 
protein synthesis and cardiomyofibril contractility (Dillmann, 1990; Klein et al., 2000, 
2001).   
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Alteration of energy production. Myocardial oxygen consumption increases in 
thyrotoxicosis. The number of mitochondria and their functional activity grows leading to 
the enhancement of adenosine triphosphate (ATP) production. However, in severe 
thyrotoxicosis, despite the increased oxygen consumption, the efficiency of its utilization 
decreases significantly. This follows altered oxidative phosphorylation resulted from the 
abnormal oxidative enzyme activity (decrease of myocardial ATP and creatine phosphate 
levels results in glycolysis activation) (Golber & Kandror, 1972).  
Direct and indirect effects on myocardial of abundant TH result in alteration of 
cardiomyofibril contractility. Direct effects involve transcription of some genes regulating 
function of cardiomyiocytes, vascular smooth muscle cells (SMC) and other structural units 
(Dillmann, 1990; Klein et al., 2000, 2001)(Fig.1).  Triiodothyronine (T3) is a biologically active 
thyroid hormone that enters cardiomyocytes through specific transporters located in the 
cellular membrane, and binds thyroid hormone receptor (THR) in the nucleus (Dillmann,1990; 
Everts et al., 1996). Nowadays two types of THR are known: homodimer (THR/THR) and 
heterodimer - 9-cis retinoic acid receptor (THR/RXR). Active forms of these receptors affect 
gene expression through binding specific DNA response elements, so called thyroid hormone-
sensitive elements (TRE), located in the promoter region of Т3-sensitive genes (Brent, 1994; 
Everts et al., 1996; Fazio et al., 2004). Gene transcription is augmented in the regions encoding 
аlpha-myosine heavy chains (MNC-а), ǿа2+-ATPase of sarcoplasmatic reticulum of the 
cardiomyocytes, ǿа2+-К+-ATPase  ǿа2+- -uretic, beta1-adrenergic receptors, troponine I and 
ǿа+-uretic peptide. Three types of myosine isoforms are distinguished: V1 consisting of the 
MNC-alpha/alpha chains, V2 – consisting of MNC-alpha/beta chains, and V3 – consisting of 
MNC-beta/beta chains. High levels of TH affect myosine isoform expression and lead to the 
enhanced synthesis of V1 isoform and decrease of V3 isoform. ATPase being more active in 
MNC-alpha/alpha myosine chains compared to MNC-beta/beta chains, the velocity of 
myofibril contractions increases (Klein & Ojamaa, 2000, 2001) (Fig.1). 
 
 
Fig. 1. Genom and nongenom effects of triiodthyronine in cardiomyocytes (from Klein& 
Ojamaa, 2000) 
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Indirect myocardial effect of abundant thyroid hormones include Ca2+ release from the 
intracellular depots and their subsequent reuptake by sarcoplasmic reticulum. The latter 
results from the enhanced Ca2+ ATPase (SERCA) expression and phospholamban 
suppression that are involved in the regulation of calcium intramyocyte concentration 
during cardiac cycle (systole and diastole). This leads to the increase of peak strain of 
cardiomyofibrils and shortening of the ventricular systole. Abundant thyroid hormone 
have been shown to induce expression of ryanodine receptors facilitating calcium (Ca2+) 
release from sarcoplasmic reticulum, thus amplifying contraction and myocardial 
hypertrophy. Moreover, high levels of TH cause intracellular calcium mobilization 
directly affecting L-type of Ca2+-channels (Dillmann , 1990, Kiss et al., 1994; Klein & 
Ojamaa, 2000, 2001)(Fig.1). 
Therefore, high levels of TH contribute to the increased myocardial contractility through  
enhanced transcription of the genes encoding heavy chains of myocine beta-isoform and 
calcium-dependent ATPase, induced protein synthesis and augmented calcium and glucose 
myocardial consumption. In addition, thyroid hormones cause 50-70% reduction of 
the systemic vascular resistance (SVR) through direct and indirect (increase of tissue 
thermogenesis and lactate hyperproduction) effects on vascular smooth muscle cells leading 
to the decrease of diastolic blood pressure (DBP) and the increase of end-diastolic left 
ventricular volume. In particular, TH are known to induce nitric oxide production causing 
vasodilatation through direct effects on vascular smooth muscle cells (Ishikawa et al., 1989; 
Klein & Ojamaa, 2000, 2001; Vargas et al., 2006). Moreover, high levels of TH lead to the 
increase of circulating blood volume and venous return through the following mechanisms: 
aldosterone-renin system activation, enhancement of erythropoietin synthesis and renal 
sodium reabsorption (Jiménez et al., 1982; Marchant et al., 1993; Klein & Ojamaa, 2000, 2001; 
Vargas et al., 2006). Renal juxteglomerular complex is activated when DBP is reduced 
(Büssemaker et al., 2003). In addition, T3 directly stimulates rennin substrate synthesis by 
liver (Ganong WF. 1982). The reduction of BP and SVR induces production of rennin and 
aldosterone resulting in the increase of circulating blood volume and end-diastolic volume 
that finally amplifies workload on heart  (Klein & Ojamaa, 2000, 2001; Vargas et al., 2006) 
(fig.2). 
 
 
 
Fig. 2. Effects of Thyroid Hormone on Cardiovascular Hemodynamics 
 The diagram shows the way in which
triiodothyronine increases cardiac
output by affecting tissue oxygen
consumption (thermogenesis), 
 vascular resistance, blood volume,
cardiac contractility, and heart rate 
(from Klein I. and Ojamaa K. 2001) 
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Tachycardia is a typical feature of thyrotoxicosis (Nordyke, 1988; Cacciatori, 1996; Biondi, 
2000). It is caused by the faster diastolic depolarization associated with the shortening of 
action potential of the sinoatrial node (Osman et al., 2002). In general, the TH effects on 
pacemaker and conductive cardiac system include acceleration of systolic and diastolic 
depolarization and shortening of action potential, as well as of refractory period of atrial 
and atrioventricular myocytes. The latter can result in the increase of AF occurrence in 
thyrotoxicosis. Other mechanisms include augmentation of the pressure in left atrium,  
ischemia  and left atrial premature ectopic heart beats (Bielecka-Dabrowa et al., 2009).  
Thyroid hormones regulate some myocardial genes encoding synthesis of ion channels 
(K+/Na+-ATPase, Ca+/Na+- exchanger and potential-depending potassium channels) in 
cell membrane. These extranuclear effects involve the transport of aminoacids, glucose 
and calcium through cell membrane. Therefore, T3 can alter the activity of various ion 
channels (including sodium, potassium and calcium channels) located in cell membrane. 
(Bielecka-Dabrowa  et al., 2009). In particular, phospholipid and Ca-dependent 
proteinkinase, cAMP-dependent proteinkinase, and Ca2+-calmodulin complex as the 
components of signal transmission system are involved in the T3 non-genomic cell effects. 
Thus, non-genomic actions of thyroid hormones include regulation of intracellular ion 
levels and their intracellular distribution. Changing transmembrane ion transport TH 
affect electrophysiologic features of cardiomyocytes (Kim & Smith, 1984).  T3-induced 
expression of L-type calcium channels leads to the following: less calcium ions enter 
cardiomyocytes through L-type channels, and action potential gets shorter (Freedberg et 
al., 1970).  
The occurrence of atrial rhythm disturbances (atrial fibrillation, atrial premature heart beats) 
is higher at thyrotoxicosis, while the rate of ventricular arrhythmias is comparable with the 
one in general population (Osman et al., 2002). Atrial and ventricular myocardial sensitivity 
to thyroid hormones is different that can be the cause of the variation in atrial and 
ventricular arrhythmia prevalence. High atrial sensitivity to arrhythmogenic thyroid effects 
is due to the high β-adrenoreceptor density at the surface of atrial cardiomyocytes and to the 
different autonomic innervation of atria and ventricles (Polikar et al., 1993; Lombardi et al., 
1994). Golf et al. (1985) found that β-adrenoreceptor density in right atria of human heart 
samplings is more than twice as high as in left ventricle. Higher β-adrenoreceptor density in 
thyrotoxicosis is associated with the greater catecholamine myocardial sensitivity. 
Androgens up-regulate expression of the β-adrenoreceptor genes leading to their density 
increase. This can explain higher susceptibility to heart rhythm disturbances in men 
compared to one of women.  
Expression of potential-dependent K+-channels in atria is 30% as high as in ventricles 
(Ojamaa et al., 1999). Expression of genes encoding both β-adrenoreceptor and potential-
dependent K+-channels depends on thyroid hormones that induce heart rhythm 
disturbances. Experimental mice studies demonstrated that duration of atrial action 
potential is shorter, and atrial delayed rectifier potassium current (ultra rapid – Ikur and 
slow – Iss) mediating repolarization is greater in thyrotoxicosis.  RNA messenger level and 
expression of genes of K+-channels (Kv1.5 и Kv2.1) were shown to be higher in both atria 
that also leads to the greater density of delayed rectifier potassium channels (Ikur и  Iss) in 
hyperthyroidism. Thyroid effects on action potential and delayed rectifier potassium current 
are more expressed in right atrium compared to left one resulting in low interatrial 
difference of action potential duration  (Bielecka-Dabrowa et al., 2009). 
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Shortening of atrial action potential in thyrotoxicosis is associated with the shorter duration 
of effective refractory period facilitating re-entry foci developing. On the other hand, normal 
interatrial difference of action potential is of great importance for synchronous atrial 
contraction (regarding right-sided location of the sinus node). Spontaneous ectopic activity, 
particularly in left atrium, can increase leading to atrial heart rhythm disturbances (atrial 
fibrillation) when the interatrial action potential difference is reduced (Bielecka-Dabrowa, 
2009).   
Pulmonary veins are known to initiate paroxysmal atrial fibrillation that can be due to the 
increased spontaneous activity of that region. Shorter action potential of the cardiomyocytes 
located in pulmonary veins associated with the shortening of refractory period and 
facilitating re-entry onset was shown in experimental thyrotoxicosis models (Chen, 2002). 
Incubation with thyroid hormones  increased spontaneous activity in pulmonary vein 
cardiomyocytes similar to its effect on sinoatrial node cells. Trigger activity is supposed to 
underlie spontaneous activity of pulmonary veins  (Bielecka-Dabrowa  et al., 2009). 
3.2 Pathogenesis of clinical manifestations of thyrotoxic cardiomyopathy 
Tachycardia in thyrotoxicosis develops due to the faster diastolic depolarization associated 
with the shortening of action potential of the sinoatrial node cells [Osman F et al. 2002]. 
Sinus bradycardia can develop in case of congenital disorders or sick sinus syndrome. The 
latter, as well as abnormal heart rhythm can result from the decreased reserves of the 
mediator acetylcholine.  
Mechanisms of arrhythmogenesis are discussed in the former chapter. Pathogenesis of heart 
rhythm disorders is not clear, and the following pathogenetic factors are being discussed: 
toxic effects of thyroid hormones, increased sympathetic activity, reduced intracellular 
potassium level (Table 2).  
 
Effects of thyroid hormones 
Pathogenesis of influence of thyroid 
hormones 
Toxic influence on myocardium 
(amplification cardiomyofibril contractility 
and hypertrophy right atrium and left 
ventricule of heart)  
Alteration oxidative phosphorylation. 
Increase synthesis of protein, action of 
enzymes, uptake of O2 
Alteration power processes and changes of 
K+/Na+-pump - increase velocity of 
diastolic depolarization 
Increase sensitivity of SNS Increase of number of 1-adrenoreceptors 
Decrease of intracellular pool of potassium 
Hyperfunction of heart and increase of 
action of simpatoadrenal influence 
Change of vascular reactivity Hyperrelaxations vascular myocites 
Table 2. Pathogenesis of arrhythmias in thyrotoxicosis 
Cardiac hyperfunction and increased adrenergic stimulation contribute the loss of 
intracellular potassium ions leading to heart rhythm disorders. Atrial dystrophic alterations 
associated with the structural myocardial heterogeneity are a confounding factor for atrial 
fibrillation. Exposure to any additional factor increasing myocardial heterogeneity can result 
in the complete myocardial uncoupling inducing heart rhythm disturbances. Atrial dilation, 
increased excitability of atria associated with the myocardial heterogeneity mediating 
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functional conductive disorders underlie re-entry arrhythmias. Re-entry associated with the 
frequent focal activity are supposed to be the main mechanism of atrial fibrillation and 
flutter in thyrotoxicosis. 
Increased cardiac output and reduced system vascular resistance (SVR) in thyrotoxicosis 
commonly lead to the amplification of pulse amplitude. Hemodynamics is altered in 
thyrotoxicosis as it has been mentioned above. The changes include elevation of heart rate, 
stroke and minute volumes, acceleration of blood flow, decrease of systemic vascular  
resistance (Fig.3), and resulting changes of blood pressure – systolic blood pressure is 
moderately increased, while diastolic blood pressure is within normal values or decreased. 
Thus pulse pressure goes up. The recent studies have demonstrated arterial stiffening and 
low SVR in thyrotoxicosis (Palmieri et al., 2004). Therefore, high levels of thyroid hormones 
cause systolic blood pressure (BP) elevation leading to isolated systolic hypertension in 
elderly patients with decreased arterial elasticity due to the atherosclerotic vascular lesion. 
The prevalence of isolated systolic hypertension is significantly higher in patients with 
thyrotoxicosis compared to euthyroid subjects (Marcisz et al., 2001). ST can resulting in an 
increase in nighttime systolic and mean blood pressure (Botella-Carretero et al, 2004).  It 
appears to be one of the factors for LVH development in thyrotoxicosis. 
 
 
Fig. 3. Effects of hyperthyroidism on the cardiovascular system and the possible 
outcomesEccentric type of LVH, as a result of low SVR and volume overload on the heart, is 
a typical feature of thyrotoxicosis. However, there are data showing both normal LV 
geometry (Levina, 1989; Babenko, 2008), and LVH (eccentric type (Levina, 1989; Marcisz et 
al., 2006; Babenko et al., 2008, 2011) as well as concentric one (Donatelli et al., 2003) in 
patients with thyrotoxicosis. It depends on the degree of cardiovascular damage influenced 
by the variety of factors that will be discussed later. 
Reduced functional cardiac reserve and physical load tolerance are also common in 
thyrotoxicosis because tachycardia at rest prevents from the increase of heart rate and 
effusion fraction and from the SVR lowering at physical load. 
Pulmonary hypertension (PH) (mean pulmonary pressure more than 25 mmHg at rest and 
more than 30 mmHg at load) is frequently reported at overt thyrotoxicosis. Pulmonary 
hypertension is often associated with valvular insufficiency (of tricuspid and mitral valves) 
TBV- total blood volume;  
LVEDV - left ventricular end diastolic 
volume; LVESV - left ventricular end systolic 
volume;  
SV - stroke volume;  
SVR - systemic  vascular resistance;    
CO - cardiac output;  
  increase;    decrease.  
Solid arrows indicate direct effects, and 
dashed arrows potential outcomes. 
 *Features for which T3 is directly 
responsible. (from A Toft, N Boon 2000) 
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due to the papillary muscles dysfunction (Whitner et al., 2005; Mercé et al., 2005). Patients 
with Graves’ disease are more likely to have myxomatous degeneration and prolapse of 
mitral valve as a consequence of endocardium involvement compared to subjects with toxic 
multinodular goiter (Kahaly, 1987).  
There are two possible mechanisms of valve involvement in Graves’ disease. First 
mechanism includes induction of glycosaminoglycan synthesis in endocardium (similar to 
one in retrobulbar space in ophthalmopathy) leading to the valve cusp thickening (Kahaly, 
1987). The second one implies the reduced tone of papillary muscles and their consequent 
overstretching resulting in prolapse of mitral valve cusps in left atrium during ventricular 
systole (Brauman et al., 1985). 
Pulmonary hypertension develops due to Kitaev reflex – spasm of pulmonary arterioles 
leading to the increase of pulmonary resistance (Okura & Takatsu, 1994). Thyroid hormones 
seem to affect pulmonary vessels in a rather different way compared to other vessels as they 
cause SVR reduction and circulating blood volume elevation. Blood pressure decreases in 
resistive vessels due to the vasodilatation effect of TH, and increases in pulmonary vessels. 
This is possibly mediated by endothelial dysfunction (Okura & Takatsu, 1994), and by the 
accelerated metabolism of pulmonary vasodilatation substances, such as acetylcholine, 
observed in patients with severe thyrotoxicosis (Okura & Takatsu, 1994; Nakchbandi et al., 
1999). In addition, autonomic imbalance, in particular, sympathetic hyperactivity and lower 
vagal tone (Burggraaf et al., 2001), caused by hyperthyroidism facilitates further pulmonary 
vasoconstriction and PH development. Autoimmune mechanism might be an additional 
factor for PH development (Yanai-Landau et al., 1995; Barst  & Loyd, 1998; James et al., 
2002). 
The diagnosis of heart failure in thyrotoxic patients is complex, because classic symptoms of 
heart failure including tachycardia and dyspnea, occur at the onset of hyperthyroidism due 
to both toxic effects of thyroid hormones on sinoatrial node and respiratory centre and 
intercostal muscles weakness. Heart failure (HF) develops in thyrotoxicosis because of the 
isotonic contraction (volume overload) of left ventricle and mixed overload (both volume 
and resistance overload) of right ventricle, thus right ventricular HF is more common for 
hyperthyroid state. Concomitant tricuspid valve insufficiency and regurgitation can worsen 
the situation (Whitner et al., 2005). Mitral valve prolapse is a common disorder in 
thyrotoxicosis, but it is rarely symptomatic.  
Heart failure (HF) associated with thyrotoxicosis is more common in elderly rather than in 
young patients, and the mechanisms are better studied in aged group. Elderly subjects 
usually have co-existing cardiovascular diseases (coronary artery disease, valvular heart 
disease, arterial hypertension) leading to the functional and structural cardiac alterations, 
thus, myocardium contractility is easily impaired in case of increased myocardial load 
caused by hyperthyroidism. Elderly patients with heart rhythm disturbances, such as atrial 
fibrillation (AF), have the highest risk of HF development, because AF is usually associated 
with the increased heart rate followed by functional impairment of cardiomyocytes. 
Younger patients without cardiovascular pathology more often develop “high output heart 
failure” (Okura & Takatsu, 1994). This type of HF is characterized by the myocardial 
hypercontractility.  HF with low output and heart chambers dilation (dilated thyrotoxic 
cardiomyopathy) can develop in young patients in case of the long-lasting severe 
thyrotoxicosis (Manger et al., 1988;  Soh & Croxson, 2008). However, long duration of 
hyperthyroidism is not always evident, so the mechanisms are not fully understood. 
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Autoimmune mechanisms were considered possible (Kahaly, 1987;  Koshiyama et al., 1996), 
but the hypothesis was denied afterwards (Fatourechi  & Edwards, 2000). Two hypotheses 
are discussed nowadays. According to the first one two diseases are supposed to coexist in 
one individual – Graves’ disease and idiopathic dilated cardiomyopathy (IDC). It is 
supported by their common pathogenesis - genetic predisposition determined by the HLA 
haplotypes (Limas & Limas, 1989; Olson et al., 1992) and common association of IDC and 
autoimmune thyroid diseases (MarkoviР et al., 2005). According to the second hypothesis 
long-lasting myocardial hypertrophy can transform into dilation, and heart chamber 
dilation can develop in untreated prolonged overt and even subclinical thyrotoxicosis (Soh 
& Croxson, 2008).  
Therefore, there are two main mechanisms of heart failure development in  thyrotoxicosis: 
1) tachycardia-induced HF with left ventricular dysfunction (left ventricular HF) is most 
common in patients with AF; 2) right ventricular HF resulted from volume overload of right 
ventricle due to the increased circulating blood volume and venous return is characterized 
by right ventricular dilation, enlargement of the tricuspid valve ring and tricuspid 
insufficiency and is frequently associated with pulmonary hypertension (Okura & Takatsu, 
1994;  Xenopoulos et al., 1996;  Whitner et al., 2005).  
Three stages of thyrotoxic cardiomyopathy are defined: hyperkinetic (with preserved left 
ventricular function, but at physical load left ventricular effusion fraction does not increase), 
normokinetic (a compensatory stage with a reversible myocardial hypertrophy and preserved 
cardiac output), and hypokinetic stage (decompensation stage with low cardiac output and 
stroke volume, either reversible or irreversible heart chamber hypertrophy and dilation).  
High occurrence of thromboembolic events (higher than in general population) is typical for 
thyrotoxicosis, and even in absence of AF. Endothelial dysfunction is a possible explanation 
for high rate of thromboembolism: altered vasodilation response to acetylcholine exposure  
(Faber et al., 2001, Napoli et al., 2001), as well as elevated level of humoral substances Von 
Willebrand factor (ǿucuianu et al., 1987;  Squizzato et al., 2007), plasminogen activator, 
endothelin (Baumgartner-Parzer et al., 1997) confirm thrombogenesis activation in 
thyrotoxicosis (Homoncik et al., 2007). ST has been recently shown to have a prothrombogenic 
effects (Horne et al., 2004; Erem, 2006).  Increased activity of Von Willebrand factor (Coban et 
al., 2006) and elevated fibrinogen level (Dörr et al., 2001) were demonstrated at ST. 
4. Clinical manifestations and diagnostic tests of thyrotoxic cardiomyopathy 
The most common symptoms of thyrotoxic cardiomyopathy are palpitations, chest pain 
(cardialgia), dyspnea, irregular heart beats. Tachycardia and heart rhythm disturbances, 
systolic hypertension, orthostatic hypotension, heart enlargement, systolic murmur maximal 
over mitral valve and bubbling rales in case of HF are the most common findings at physical 
examination. Tachycardia at rest and during sleep and significant increase of heart rate at 
minimal physical exertion are typical for thyrotoxicosis. Tachycardia is position-independent 
and resistant to therapy by cardiac glycosides. Usually there is a direct relation between 
tachycardia intensity and the severity of diffuse goiter. Heart rate increases up to 120-140 beats 
per minute, and up to 160 beats per minute and more on movement, at physical and emotional 
exertion. Patients complain of pulsation in the neck, head and abdomen. Atrial fibrillation can 
develop in both clinical thyrotoxicosis and subclinical and latent forms. Thus, as a potential 
cause thyrotoxicosis should be excluded in all patients with persistent atrial fibrillation 
resistant to antiarrhythmic drugs. Thyroid dysfunction is the cause of 46% of arrhythmias of 
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this type. Paroxysmal atrial fibrillation at the onset of thyrotoxicosis usually turns into 
permanent form with the progression of the disease. There is a particular form of 
thyrotoxicosis characterized by paroxysmal atrial fibrillation with normal sinus rhythm or 
bradycardia without any other symptoms of thyrotoxicosis. The level of thyroid hormones is 
crucial to make the diagnosis in such cases. Physical examination reveals tachycardia and 
ascending apex beat. The cardiac borders are expanded to the left, the heart sounds are 
intensive, first heart sound is loud, and systolic murmur can be heard. Systolic blood pressure 
is increased, while diastolic blood pressure is within normal values or decreased (resulting in 
high pulse pressure, or pulse amplitude). Water retention is usual, and edema can be found 
even in patients with preserved ejection fraction. If the symptoms are persistent after 
successful treatment of thyrotoxicosis coexistent cardiovascular pathology should be excluded. 
In otherwise healthy individuals palpitations are associated with female sex and age older 
than 50 years, dyspnea is linked to female sex and increased level of T4>30 pmol/l. After 
euthyroid state restoration dyspnea can persist in smoking subjects (Osman et al., 2007).  
Heart failure is associated with the pleural effusions, and right ventricular heart failure is 
more prevalent in diffuse goiter (Levina, 1989). Patients with dilated thyroid 
cardiomyopathy reveals cardiomegaly and pulmonary congestion (Soh  & Croxson, 2008) 
and all spectre clinical sins of heart failure. 
Diagnosis. ECG changes include high, sharp P and T waves, atrial fibrillation, and 
extrasystole. ST segment depression and T wave inversion might be also present without 
angina pectoris, and are due to metabolic changes. ECG changes are reversible if the thyroid 
hormone levels are normalized.  
Dilation of both ventricles and conus pulmonalis expansion are typical radiological signs in 
severe thyrotoxicosis. Conus pulmonalis expansion and right ventricle enlargement form 
mitral configuration of the heart. However, there is no left atrium enlargement at oblique 
view unlike the changes in mitral stenosis.  
Pulmonary edema is another radiological sign in thyrotoxicosis. Echocardiography finds left 
ventricular hypertrophy including posterior wall and interventricular septum thickening, 
increase of end-diastolic volume and of left ventricular myocardial mass. Mitral valve 
prolapse is a common finding in thyrotoxicosis. The dilation of all heart chambers and 
decreased systolic function of left ventricle can be found in dilated thyrotoxic 
cardiomyopathy.  
Perfusion scintigraphy of the heart with thallium chloride 201 demonstrates diffuse or 
small-focal decrease of cardiomyocyte metabolic activity. This diagnostic method enables 
assessment of the intact cardiomyocytes, and is helpful to exclude myocardial damage at 
early stages of the disease.  
Stress-echocardiography is useful for assessment of functional myocardial reserve.  
Increased levels of thyroid hormones and TSH suppression are crucial parameters to 
confirm the underlying cause (thyrotoxicosis) of the clinical findings.  
5. The impact of various factors in clinical manifestations of thyrotoxic 
cardiomyopathy  
5.1 Left atrial dilation and atrial fibrillation 
Right atrial hypertrophy associated with dilation and verified by ECG was found in 30.5% 
of patients with thyrotoxicosis, left atrial hypertrophy – in 13.7%, and the hypertrophy of 
both atria was found in 11.8% patients.  
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Atrial fibrillation occurrence in thyrotoxicosis widely varies depending on the studied 
population. Age, sex, severity and intensity of hyperthyroidism, and concomitant 
cardiovascular diseases affect the incidence of atrial fibrillation.  
Age-dependence is well-known: the risk of AF development increases as patients get older. 
Thus, at 10-year follow-up the incidence of atrial fibrillation was 25% in patients over 65 years 
of age with thyrotoxicosis, even its subclinical form, and this is threefold risk of patients with 
normal TSH (7%). The prevalence of AF was 21% in total cohort patients with clinical 
thyrotoxicosis (Iwasaki T  et al, 1989), and 31% in subjects over 40 years old, while there was 
no single case of AF in individuals younger than 40 years. In another study 25% of thyrotoxic 
subjects over 60 years old had AF compared to 5% in younger group (Agner et al., 1984).  
Regression analysis performed by Nakazawa H. (2000) demonstrated a clear age-dependence 
of AF prevalence increasing stepwise till the maximal values in patients older than 70 years.  
Male sex is another risk factor for AF  (Staffurt et al., 1977). Toft A. & Boon N (2000) 
reported up to 50% prevalence of AF in males aged 60 years with hyperthyroidism.  
The impact of the duration of thyrotoxicosis is less investigated. AF is quite rare (less than 
2%) at onset of overt thyrotoxicosis (Nakazawa et al., 2000) and in patients under 40 years 
old without concomitant cardiovascular diseases Toft A. & Boon N (2000). The following 
factors are considered the most significant for AF development in young subjects without 
concomitant cardiovascular pathology: thyrotoxicosis duration (Ȟ=0,0005, OR=72 (6,6-794)), 
male sex (OR=10,4 (3,0-36,0), Ȟ=0,0003), and heart rate (OR=1,07 (1,03-1,11) Ȟ=0,0001) ( 
Babenko et al., 2011). These factors are also important in case of coexistent heart pathology. 
Having examined 40 628 patients with thyrotoxicosis Frost (2004), showed that the highest 
risk of AF is associated with male sex, coronary artery disease and congestive HF. J. Mercé 
et al. (2005) found higher occurrence of AF in thyrotoxic patients with symptomatic 
insufficiency of either mitral or tricuspid valves (40% vs. 14%, P=0,02 in mitral regurgitation, 
and 86% vs. 3%,P=0,01 in tricuspid regurgitation). 
Data on the effect of thyrotoxicosis intensity (overt or subclinical) are controversial. Auer et 
al.(2001)  reported similar relative risk of AF in both subclinical and overt thyrotoxicosis 
(12,7 % and 13,8%, respectively). According to other data, AF occurrence in ST was 7% 
compared to 16% in clinical thyrotoxicosis (Babenko et al., 2011).  There is an association 
between atrial fibrillation occurrence and type of predominantly elevated thyroid hormone 
(T3 or T4). Thus, atrial fibrillation occurs in 36% patients if T3 is elevated, in 13% - if T4 is 
increased, and in 21% - if the levels of both thyroid hormones are high. Therefore, the 
highest occurrence of atrial fibrillation was observed in the thyrotoxicosis due to isolated T3 
excess. However, the difference could be explained by the different duration of the disease: 
isolated T3 thyrotoxicosis develops in nodal thyroid autonomy that is characterized by the 
long-term asymptomatic period and slow increase of thyroid hormone level at first leading 
to subclinical thyrotoxicosis, and then to T3 thyrotoxicosis. Conversion to sinus rhythm was 
reported only in 19% of patients with atrial fibrillation and at subclinical thyrotoxicosis. Risk 
factors for atrial fibrillation are listed in table 3.  
Standard ECG could be used to identify high-risk patients at subclinical thyrotoxicosis: 
those with a short P-R interval who are predisposed to reentrant atrioventricular nodal 
tachycardia (Biondi B et al, 1998) and those with higher maximum P wave duration and P 
wave dispersion who are predisposed to AF (Aras D et al, 2005). In predisposed patients 
(those with two functionally distinct AV nodal conduction patterns), l-thyroxine (l-T4) 
suppressive therapy may increase the occurrence of reentrant-atrioventricular nodal 
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tachycardia because of the enhanced atrial excitability, which increases the number of atrial 
premature beats, and the shortening of the refractory period of the conducting tissue (Biondi 
B et al, 1998). Moreover, by measuring P maximum and P wave dispersion values, one could 
theoretically identify the patients with ST that are at high risk of AF (Aras D et al, 2005). 
Holter ECG could be performed before starting l-T4 treatment in doses that suppress TSH to 
potentially identify patients who may be less tolerant to l-T4 treatment. 
 
Age 
Male sex 
Duration of hyperthyroidism 
Heart rate 
Concomitant cardiovascular diseases 
Table 3. Risk factors for atrial fibrillation development.  
5.2 Left ventricular hypertrophy 
LVMMI is influenced by T3 level, systolic BP level and body mass index in patients with 
thyrotoxicosis (Marcisz et al., 2006). Eccentric left ventricular remodeling is predominant, 
and treatment and restoration of euthyroid state is not associated with LVMI normalization 
(9-month follow-up).  
Sex also affects the occurrence of left ventricular hypertrophy (LVH) in thyrotoxic patients: 
the incidence of LVH is higher in men than in women (21,3% vs. 30,6%, respectively, 
OR=3,6; CI (1,8; 7,4); Ȟ=0,05). Eccentric type of LVH was present in 18,2%, and concentric 
one – in 4,3%, concentric remodeling occurred in 7,4% of patients (Babenko et al., 2011).  
LVH rate increases in older population, however, the age-dependence is different in men 
and women. Correlation between LVMI and age is significant in general population (r=0,22, 
p=0,0007), and in females (r=0,27, p=0,0002), compared to non-significant association in 
males (r=0,10, p=0,58). More precise analysis showed that these parameters are related 
nonlinearly, and variability of LVMI increases in older subjects. Non-linear regression 
analysis defined an age threshold of 44 years: LVMI does not change up to this limit, and 
increases rapidly in older subjects for more than 10 g/m2. It is even more evident in females: 
mean LVMI is 90±20 g/m2 in women younger 44 years, and 105±25 g/m2 - in older ones. 
The prevalence of left ventricular hypertrophy increases significantly from 11 up to 36% 
(OR=4,4; CI (2,1; 9,1), Ȟ=0,0002). Similar LVMI increase is observed in males – from 117±27 
to 124±36 g/m2, but changes of LVMI values and LVH prevalence are not significant 
because of the high LVMI variability (and smaller group) (Ȟ=0,63) (Babenko et al., 2011).  
Atrial fibrillation is another factor associated with both LVH presence and severity (LVMI 
value) (Babenko et al., 2011). 
The factors affecting left ventricular hypertrophy in subclinical thyrotoxicosis are not 
completely established. Shapiro L.C. et al. (1997) did not find LVH development in long-
lasting ST (9,2±5,4 years) and very low TSH – 0,001 mIU/l in subjects with endogenous ST 
(mean age 45±10 years (27-63)). Biondi B. еt al. (2000) reported significant increase of LVMI 
(162±24 g/m2) in an age-matching group (439 years (27-69)) with endogenous ST but with 
higher TSH values (0,15  mIU/l) and shorter duration of subclinical thyrotoxicosis (6 
months), however, it should be mentioned that 80% of the group were women. The same 
authors (Biondi et al., 1999) also demonstrated positive correlation between LVMI and 
duration and dozing of L-thyroxin treatment in patients with endogenous ST. There is 
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evidence of different underlying mechanisms of LVH development in clinical and 
subclinical thyrotoxicosis (Donatelli et al., 2003), although the degree of LVH is comparable. 
LVH was shown to develop even in ST with normal heart rate, blood pressure and systolic 
left ventricular function that indicates the direct trophic effect of TH.  
LVMI is higher in patients with subclinical thyrotoxicosis of variable etiology (iatrogenic, 
autoimmune hyperthyroidism caused by subclinical Graves’ disease and nonimmune 
hyperthyroidism at pretoxic thyroid adenoma) compared to age- and sex-matching control 
group (Ȟ<0,005). LVH prevalence is 39% (43 patients, 45,5% in males and 38,4% in females) 
in ST. There was no difference in etiology and duration of ST. Male sex is a risk factor for 
LVH in ST as well as in clinical hyperthyroidism (Babenko et al., 2011). 
Age and systolic blood pressure are two other risk factors for left ventricular hypertrophy 
(Babenko et al., 2007). Therefore, risk factors for left ventricular hypertrophy and atrial 
fibrillation development are different (Table 4)  
 
Age 
Male sex 
Duration of thyrotoxicosis 
Systolic blood pressure 
Concomitant cardiovascular diseases 
Table 4. Risk factors for left ventricular hypertrophy  
5.3 Pulmonary hypertension 
J. Mercé et al. (2005) analyzed data on pulmonary hypertension and its risk factors. 
Pulmonary hypertension (PH) occurs in 41% of thyrotoxic patients. Patients with 
thyrotoxicosis and symptomatic mitral or tricuspid insufficiency have higher pulmonary 
pressure: 53,8 vs. 34,9 mmHg, P=0,0001 in mitral insufficiency, 43,9 vs. 35,12 mmHg, P 
=0,07 in tricuspid insufficiency. There is no relationship between PH and following 
factors: age, sex, the cause of hyperthyroidism, cardiovascular or other symptoms, heart 
rate and type of heart rhythm disturbance, the level of thyroperoxidase antibodies, TSH, 
and TH.  Pulmonary hypertension persisted in 16% of subjects after euthyroid state 
restoration. We found 39% prevalence of PH in thyrotoxicosis, and pulmonary pressure 
lowered till normal values in 61.5% of patients after persistent euthyroidism was 
achieved. The increase of pulmonary pressure was associated with free thyroxine level 
before treatment (r=0,5, p=0,0001), age (r=0,25, p=0,002) and endothelial vasodilatation 
function (the lower the response in reactive hyperemia test, the higher pulmonary 
pressure, r=-0,37, p=0,002). Right ventricular diameter positively correlated with 
pulmonary pressure (r=0,36, p=0,0001), and was considered a predictor of PH as there 
was 100% elevation of pulmonary pressure in patients with initial right ventricular 
dilation and normal pulmonary pressure.  
According to our data pulmonary hypertension occurs in 29.6% of patients with subclinical 
thyrotoxicosis. The occurrence was highest (37,5%) in subjects with endogenous nonimmune 
ST (autonomic thyroid nodules). Free T3 and the degree of TSH suppression had the 
greatest impact. Thus, there was a positive correlation between pulmonary pressure and 
free T3 level (r=0,56, p<0,001), and negative – with TSH (r=-0,34, p<0,005).  Higher level of 
T3 appears to be the reason of the greater elevation of pulmonary pressure in nonimmune 
endogenous ST (Babenko et al., 2008). 
www.intechopen.com
  
Cardiomyopathies – From Basic Research to Clinical Management 
 
568 
5.4 Heart failure 
Risk factors of heart failure (HF) development in thyrotoxicosis are not well understood. As 
reported by Siu C-W et al. (2007), 5.8 % thyrotoxic patients developed heart failure, and AF 
was an independent predictor of HF (OR 37,4, (CI 9,72- 144,0, p <0,001)). 47% had left 
ventricular dysfunction (EF < 50%) that was more severe in patients with the lowest serum 
TSH level. Male sex was related with heart failure development (OR 26,6 (CI 2,6-272,5), p = 
0,006). Left ventricular dysfunction and heart chamber dilation were present in one third of 
patients with restored euthyroidism. Patients with preserved output (ejection fraction 55% 
vs. 30 %, p <0.001) and lower functional class of heart failure (NYHA) demonstrate better 
outcome (reverse changes) (1.2 (0.1) vs. 2.5 (0.2), p <0.001).  
The following main predictors of HF development in thyrotoxicosis (Babenko et al., 2011) 
are defined by multifactorial analysis: systolic blood pressure and free T3 level before 
treatment, dilation of left ventricle and to a lesser extent of other heart chambers.  
To sum up, duration of hyperthyroidism, sex (male) and age are the main predictors of 
development of thyrotoxic cardiomyopathy and its clinical manifestations (left atrial 
dilation, atrial fibrillation, LVH, HF).  
6. Predictive and therapeutic approach to thyrotoxic cardiomyopathy based 
on its risk stratification 
Therapeutic approach should consider the factors affecting developing of thyrotoxic 
cardiomyopathy (TCMP) because persistent cardiac alterations have negative impact on 
cardiovascular prognosis.  
European guidelines on management of toxic diffuse goiter offer the following strategy: 
conservative treatment by antithyroid drugs should be administered for 18 months with the 
following withdrawal in case of remission achieved, otherwise non-medication (irreversible) 
treatment is strongly recommended.  
Persistent euthyroid state achievement is of great importance in management of thyrotoxic 
cardiomyopathy  symptoms, while greater duration and older age are associated with worse 
cardiovascular prognosis. In our study (Babenko et al., 2011) median duration of 
hyperthyroidism was 10 (6; 16) months in women without left ventricular hypertrophy (LVH) 
and 10 (6; 15) in men, while it was up to 20 (9; 40) months in women with LVH (Ȟ=0,006) and 
up to 19 (12; 30) in men with left ventricular hypertrophy (Ȟ=0,09). Therefore, left ventricular 
hypertrophy  risk is low in thyrotoxicosis lasting for less than 10 months, but it is significantly 
higher in more prolonged disease. In addition, left ventricular hypertrophy risk was higher in 
women over 44 years old, but it was age-dependent in men. Age and sex differences should be 
considered in clinical practice, and early non-medication treatment (after 8-10 months of 
antithyroid therapy) should be recommended in all male subjects and in women older 44 
years. On the other hand, left ventricular hypertrophy in a newly diagnosed thyrotoxicosis is 
the sign of the long-lasting pathology, and its total duration is longer than mentioned periods. 
These subjects should undergo irreversible treatment earlier. Systolic hypertension worsens 
cardiovascular prognosis and it must be effective curation. 
The choice of non-medication therapy– surgery or radioiodine intervention – is not easy in 
patients with thyrotoxic cardiomyopathy. Surgical treatment is associated with the high 
peri- and intraoperative risk, and radioiodine therapy is linked to the worse prognosis. The 
latter is due to the radioactive thyreoiditis development leading to the “leakage” 
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thyrotoxicosis, causing atrial fibrillation recurrence, vasospasm and cardiovascular events 
(myocardial infarction, stroke, pulmonary thromboembolism). I131 treatment is associated 
with the high early mortality at 1-2 months after intervention that coincides with the time of 
radioactive thyreoiditis onset.  
Because increasing cardiovascular risk is present in older ST patients, treatment of endogenous 
ST (antithyroid drugs or radioiodine) is recommended to these patients. Restoration of 
euthyreoidism improves cardiovascular parameters (reduction in heart rate and the number of 
atrial and ventricular premature beats, LVMI and cardiac output) (Biondi and Cooper, 2008).  
At older patients it is necessary to avoid whenever possible exogenous SТ. Recent guidelines 
do not recommend suppressive therapy with l-T4 (to suppress serum TSH to below 0.1 
mIU/liter) of benign thyroid nodules. Long-term suppressive therapy with serum TSH 
concentrations below 0.1 mIU/liter is recommended for DTC patients with persistent 
disease and a high risk of recurrence. Beta-blockade might be considered in high-risk 
thyroid cancer patients with adrenergic hyperresponsiveness to l-T4 (Biondi et al, 2005). 
Symptomatic therapy of thyrotoxic cardiomyopathy should consider underlying pathogenetic 
mechanisms. Regarding high β-adrenoreceptor density, tachycardia due to increased 
adrenergic activity and volume heart load, β-blockers and diuretics should be administered. 
Diuretics are of great importance in patients with congestion symptoms (edema, dyspnea). 
Beta-blockers do not influence the release of thyroid hormones and are used to decrease 
sympathetic hyperactivity, thus leading to the reduction of cardiac load and myocardial 
oxygen demand. The choice of β-blocker is a highly debated question till nowadays. On the 
one hand, antithyroid activity of non-selective β-blockers (e.g. propranolol) is well-known . 
There is evidence that beta-blockers (propranolol) affect metabolism of thyroid hormones by 
inhibition of deiodinase type 2 in different tissues including cardiomyocytes and contributing 
transformation of T4 to inactive T3 – reversible hormone (Fig 4). 
 
 
Fig. 4. Structures and interrelationships between the principal iodothyronines activated or 
inactivated by the selenodeiodinases (from A. Bianco, 2002) 
www.intechopen.com
  
Cardiomyopathies – From Basic Research to Clinical Management 
 
570 
Deiodinases are the selenoenzymes regulating thyroxine (T4) transformation into 
triiodothyronine (T3) (Bianco et al. 2002, Kohrle, 1999). Type 1 deiodinase (D1) is present 
in liver, kidneys and thyroid gland (Bianco et al. 2002, Peeters et al. 2003) and is supposed 
to play the key role in active circulating hormone T3 production (Kohrle, 1999). Type 2 
deiodinase (D2) enables T3 production in the following tissues: central nervous system, 
pituitary gland, brown adipose tissue, myocardium, somatic muscles, osteocytes; and it is 
less expressed in liver and kidneys (Bianco et al. 2002, Kohrle, 1999, Peeters et al 2006). 
Thus, D2 plays the key role in local tissue T3 production, however D2 activity in somatic 
muscles makes a major contribution to serological markers output (Peeters et al, 2006, 
Maia, 2005) . Therefore, free T3 concentration in tissues depends on both T4 synthesis in 
thyroid gland and, correspondingly, circulating T4 concentration, and deiodinase activity 
in tissues. D1 contribution varies from 15-39% in the most of studies to 80% (Bianco et al. 
2002, Pilo, 1990) (fig.5). T3 tissue concentration less depends on plasma thyroid hormone 
levels as D2 activity can contribute to a larger T3 tissue output. As a result, T3 
concentration differs a lot in various organs and tissues. For example, T3 saturation 
usually is about 50% in liver and kidneys while it amounts to 95% in central nervous 
system (Bianco A et al. 2002).  According to scientific data, type 2 deiodinase activity rises 
many times in some tissues in patients with Graves’ disease. Thus, high D2 activity was 
revealed in thyroid tissue extracted from patient with Graves’ disease at surgery 
(Salvatore et al, 1996). There are data showing that thyrotoxicosis clinical manifestations 
do not always correlate with circulating thyroid hormone concentration. B.Biondi et al. 
(2000) using questionnaire (with special symptoms scale) revealed manifested thyrotoxic 
symptoms in some patients with subclinical thyrotoxicosis. Cardiovascular examination 
of these patients (Echocardiography (EchoCG), bicycle ergometry, electrocardiography, 
etc.) also revealed severe pathologic changes (high atrial arrhythmia prevalence, left 
ventricular hypertrophy, diastolic dysfunction). 
Heart lesions similar to ones described in thyrotoxicosis patients were revealed in 
experiments involving mice with induced high D2 gene expression activity in 
cardiomyocytes (Pachucki et al, 2001). 
Based on these data it was supposed that the severity of many pathologic changes including 
cardiovascular abnormalities in patients with Graves’ disease can be associated with both 
circulating hormone level and deiodinase-dependent T3 tissue production. In particularly, 
energy consumption in skeletal muscles was shown to correlate with free thyroxin (FT4) and 
TSH circulating levels, but not with free triiodothyronine level (FT3) (Canani  et al, 2005). 
Type 2 deiodinase is assumed to play the key role in T3 tissue concentration changes, at 
least, in the tissues (such as myocardium, vessel wall) with high D2 gene expression. 
Latter studies showed clinical impact of certain polymorphisms of deiodinase genes. One of 
these is found in humans and includes D2 polymorphisms characterized by threonine (Thr) 
changed for alanine (Ala) in codone 92 (D2 Thr92Ala). 
Ala/Ala homozygous patients demonstrate lower D2 tissue activity compared to Аlа/Thr 
heterozygous and Thr/Thr homozygous patients. Therefore, this polymorphism can 
decrease T3 effects in tissues with high D2 gene expression (Bianco et al. 2002, Kohrle, 1999). 
Therefore, this polymorphism is suggested to influence clinical manifestations and the 
severity of heart damage in patients with thyrotoxicosis. 
Our study shows that Thr92Ala D2 polymorphism can impact clinical course of Graves’ 
disease and heart damage  (Grineva et al, 2009). 
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Fig. 5. Pathways of T3 production in humans and rats. The dotted lines in the cylinder 
representing human extrathyroidal production reflect the uncertainty about the exact 
contributions of D1 and D2 to this pool. Values given are based on the studies cited in the 
text. Values for rats are normalized to 100 g body weight (from A. Bianco, 2002) 
T3 level and T3/T4 index before treatment are considered as predictors of Graves’ disease 
remission. We show significant differences between these parameters depending on 
Thr92Ala D2 polymorphism occurrence prove its role as a predictor of Graves’ disease 
prognosis. It is confirmed by considerable difference in disease duration in groups of 
patients with various genotype. Thr92Ala D2 polymorphism seems to be protective as 
disease duration and relapse prevalence were considerably lower in Ala/Ala homozygous 
patients. This leads to inhibition of T3 effects in tissues with high D2 expression, such as: 
heart, thyroid and pituitary gland. Our data prove that Thr92Ala D2 polymorphism can 
impact clinical manifestations of Graves’ disease including thyroid volume gain and heart 
rate. Ala/Ala homozygous patients reveal lower heart rate than heterozygous and Thr/Thr 
homozygous ones. All these clinical features (lower hormone level and heart rate, less 
thyrotoxicosis duration) contribute to less severe thyrotoxic cardiomyopathy in Ala/Ala 
homozygous patients. 
Ala/Ala genotype of D2 polymorphism is also protective lowering total LVH risk and  
negative prognostic types of remodeling (concentric hypertrophy and dilatation of 
chambers), in particular. Therefore, medications leading to the decrease of deiodinase 2 
activity could result in the reduced clinical manifestations of TCMP, however, no evidence 
is still available (Grineva et al, 2009).  
However, only high doses of propranolol (more than 160 mg daily) can significantly 
decrease T3 plasma level (for approximately 30%), and it can result in severe reduction of 
blood pressure in the majority of patients (normotensive ones) as far as only some of them 
develop systolic hypertension.  
On the other hand, β1-adrenoreceptor density is the first to be increased in thyrotoxicosis. 
Selective β1-blockers are supposed to be more effective. However, the advantage of any 
certain β-blocker in TCMP management is not evident, thus, the choice is based on the other 
advantages, e.g. dosage: once- or twice-daily drugs are preferred. It should be stated that 
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elderly subjects as well as patients with low output HF and low blood pressure level are at 
high risk of hypotension (in particular, postural hypotension)  development when treated 
by beta-blockers. (15)Low doses of cardioselective beta-blockers – betaxolol, atenolol, 
metoprolol – are preferable in this group of patients and in subjects who have relative 
contraindications (eg. bronchial obstruction) to beta-blockers. Beta-blockers are usually 
administered while euthyroid state is achieved, and then the doses are gradually 
diminished and withdrawn, in some cases if necessary low doses are maintained for a long 
time. The latter includes sustained tachycardia resistant to antithyroid therapy, heart 
rhythm disturbances such as extrasystole and atrial fibrillation; heart failure due to the 
forceful cardiac contractions. Beta-blockers are also used before the effects of antithyroid 
drugs or radioiodine are apparent, as well as in thyrotoxic storm and as a part of 
preoperative care.  
Combination therapy by beta-blockers and antithyroid drugs has certain cardiovascular 
benefits compared to monotherapy. However, individual beta-blocker susceptibility should 
be assessed. Decrease of heart rate and absence of side effects are the main signs of the 
correct dosing. Significant positive clinical effect is usually apparent after 5-7 days of 
therapy by beta-blocker, including reduction of sympathetic hyperactivity and related 
symptoms, decrease of heart rate (in sinus rhythm as well as in atrial fibrillation), 
extrasystoles are less frequent or disappear, in some cases atrial fibrillation converts to sinus 
rhythm.  
In patients with exogenous ST, the administration of a beta-blocking drug reduced the 
increased heart rate and left ventricular mass (Fazio et al, 1995). Therefore, beta–adrenergic 
blocking drugs should reduce the cardiovascular risk, and thus they might be considered for 
patients requiring long-term TSH suppressive therapy, especially symptomatic patients 
with high-risk thyroid cancer in which more aggressive TSH suppression may be required 
(Biondi and Cooper, 2008). 
Cardiac glycosides usually are not indicated in thyrotoxicosis even in patients with severe 
HF.  They lead to systole enhancement, diastole prolongation, being vagotropic they slow 
down cardiac conductivity, in particular atrioventricular conduction. Thyrotoxicosis is 
characterized by hyperkinetic hemodynamics, delayed atrioventricular conduction, and 
cardiac glycosides are even dangerous as digitalis intoxication easily develops. Thyrotoxic 
patients are usually resistant to antiarrhythmic drugs, and amiodarone (containing one 
third of iodine) can induce severe therapy-resistant thyrotoxicosis, including thyrotoxic 
crisis.  
Efficacy of AF treatment depends on several factors. Younger age (under 50 years), 
absence of HF symptoms or other coexistent cardiovascular pathology, short duration 
(<4 month) and paroxysmal AF, normal systolic blood pressure and fast hypothyroidism 
achievement by antithyroid medication are the main predictors of sinus rhythm 
restoration that is observed in about one third of patients. Spontaneous conversion 
to sinus rhythm usually occurs at 3-month persistent euthyroid state. Otherwise 
standard guideline-based management of atrial fibrillation should be applied. The 
indirect relation between probability of successful  cardioversion and duration of atrial 
fibrillation from any cause should be considered before the procedure (either 
pharmacologic or electrical cardioversion). Warfarin should be prescribed in patients 
with persistent AF, or aspirin should be considered in case of contraindications to 
anticoagulation therapy.  
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7. Conclusion – Up-to-date prevention of thyrotoxic cardiomyopathy and 
future prospects  
LVH used to be considered reversible in TCMP patients as it was mentioned above. In basic 
animal research thyroxine induced LVH was found to be completely reversible when 
euthyroidism was achieved. Nixon et al. (1979) and Ching et al.(1996) demonstrated LVMI 
reduction after euthyroidism restoration in patients with thyrotoxicosis. However, it was 
not proven in more prolonged studies when thyroid function was normalized by thymasol 
therapy (Merillon et al.1989, Makaruk et al., 1998), According to Marcisz et al (2006) cardiac 
function and output, as well as systolic blood pressure were altered even after euthyroid 
state was restored, compared to healthy control group. It could result from TH-induced 
expression of the genes of contractile proteins and β-adrenoreceptors. Reversible changes 
might not be complete and would take longer time.  
Beta-adrenergic effects have been investigated for years. Some authors confirmed beta-
blocker benefits for LVH prevention in animal models, while others did not. A number of 
articles have been recently published regarding the impact of rennin-angiotensin system on 
LVH development and potential role of angiotensin converting enzyme inhibitors (ACEi) in 
LVH prevention and treatment in thyrotoxicosis. However, all available data are provided 
by experimental studies. As far as LVH is a common indication for ACEi we studied their 
effects in humans with TCMP. We found non-complete, but more pronounced reverse 
changes of LVH and left atrial dilation in patients treated by ACEi (Babenko et al. 2006).  
Therefore, recent studies demonstrated high risk of irreversible LVH and left atrial dilation 
in AF in prolonged thyrotoxicosis and/or in elderly patients. The risk is high even after 
euthyroidism restoration by antithyroid medication. Beta-blockers and ACEi contribute to a 
better reversibility of the alterations, but complete recovery is not observed. Therefore, non-
reversible (non-medication) treatment seems to be beneficial in a high-risk patients (males, 
women over the age of 44 years, systolic hypertension) regarding TCMP prevention.  
Delayed diagnosis of thyrotoxicosis is of great medical importance as TCMP may manifest 
at first examination. These patients should be considered for non-medication treatment 
immediately after euthyroidism is restored.  
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